Promoted Content
Promoted Content

Find Drugs for Pulmonary/Respiratory Diseases in Phase I Clinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Taladegib

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ENV-101

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Omega Funds

            Deal Size: $62.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing January 07, 2021

            Details:

            Proceeds from the financing will be used to advance taladegib, an inhibitor of the Hedgehog pathway, into two Phase 2 clinical studies for the treatment of idiopathic pulmonary fibrosis (IPF) in 2021.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): FP-025

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: FP-025

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $47.0 million Upfront Cash: Undisclosed

            Deal Type: Financing December 24, 2020

            Details:

            The proceeds of the Public Offering will be used for supporting Foresee’s existing drug research and development programs – such as FP-025, for which a Phase II/III clinical trial IND application was recently submitted to the FDA for the treatment of ARDS in COVID-19 patients.

            European Biomedical Research Institute of Salerno

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Larazotide Acetate

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AT-1001

            Highest Development Status: Phase I Product Type: Peptide

            Partner/Sponsor/Collaborator: European Biomedical Research Institute of Salerno

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration December 21, 2020

            Details:

            EBRIS and 9 Meters have entered into a material transfer agreement for drug supply sufficient to initiate and complete a Phase 1 study in Australia in 2021 to assess the safety and tolerability of larazotide when delivered directly to the lungs.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VR588

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: VR588

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Vectura Ltd

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement November 30, 2020

            Details:

            This agreement provides an opportunity for Vectura to realise value from its historical research and investment in VR588, whilst expanding its CDMO development services portfolio by supporting the product's further development with Kinaset.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BBT-877

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BBT-877

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Termination November 09, 2020

            Details:

            Bridge Biotherapeutics and Boehringer Ingelheim have mutually agreed on the termination of the Collaboration and License Agreement entered into in July 2019 to develop BBT-877 for the treatment of idiopathic pulmonary fibrosis and various fibrotic diseases.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ETD002

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ETD002

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

            Deal Size: Undisclosed Upfront Cash: $96.8 milion

            Deal Type: Acquisition October 07, 2020

            Details:

            Enterprise Therapeutics' TMEM16A portfolio includes ETD002, first of its compounds to hit clinical stage. In pre-clinical models the compound has been found to enhances the activity of TMEM16A.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Itolizumab

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: EQ001

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 17, 2020

            Details:

            These findings suggest the CD6-ALCAM pathway may contribute in multiple ways to asthma pathology. These data support Equillium’s ongoing clinical development of itolizumab for the treatment of patients with moderateto-severe uncontrolled asthma.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ATYR1923

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: KRP-R120

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: KYORIN PHARMACEUTICAL CO LTD

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 11, 2020

            Details:

            Kyorin Holdings has initiated clinical development in Japan for aTyr’s lead therapeutic candidate ATYR1923 (known as KRP-R120 in Japan) following the Pharmaceutical and Medical Devices Agency (PMDA) review of its Clinical Trial Notification (CTN) submission.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ARINA-1

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ARINA-1

            Highest Development Status: Phase I Product Type: Undisclosed

            Partner/Sponsor/Collaborator: White Rock Capital Management

            Deal Size: $8.1 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing June 18, 2020

            Details:

            Funds to be used for the development and clinical programs associated with Renovion's lead therapeutic candidate ARINA-1. ARINA-1 is a nebulized therapy developed to improve mucus clearance and decrease inflammation in patients diagnosed with chronic lung disease.

            Imperial College London

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TRV027

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Trevena

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 02, 2020

            Details:

            Collaboration to evaluate the potential of TRV027, a novel AT1 receptor selective agonist, to treat acute lung injury contributing to acute respiratory distress syndrome (ARDS) in COVID-19 patients.